Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
19.35 USD   +2.65%
05/26CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K
PU
05/26CUREVAC N : Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development - Form 6-K
PU
05/26CUREVAC N : Announces Financial Results for the First Quarter of 2022 and Provides Business Update - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Drifting Lower in Friday Trade

01/21/2022 | 01:08pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APPLIED DNA SCIENCES, INC. 4.24% 1.23 Delayed Quote.-69.40%
CUREVAC N.V. 2.65% 19.35 Delayed Quote.-43.60%
MEDTRONIC PLC -0.36% 99.08 Delayed Quote.-4.22%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
All news about CUREVAC N.V.
05/26CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
PU
05/26CUREVAC N : Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Va..
PU
05/26CUREVAC N : Announces Financial Results for the First Quarter of 2022 and Provides Busines..
PU
05/25CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/25CureVac N.V. and myNEO N.V. Enters into a Research and Option Agreement
CI
05/25CureVac Working With myNEO to Develop New mRNA Immunotherapies
MT
05/25CureVac Narrows Q1 Pre-Tax Loss as Revenue Rises
MT
05/25CureVac Announces Financial Results for the First Quarter of 2022 and Provides Busines..
EQ
05/25CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vac..
EQ
05/10TRANSCRIPT : CureVac N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2..
CI
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2022 76,6 M 82,0 M 82,0 M
Net income 2022 -130 M -140 M -140 M
Net cash 2022 507 M 543 M 543 M
P/E ratio 2022 -26,0x
Yield 2022 -
Capitalization 3 378 M 3 619 M 3 619 M
EV / Sales 2022 37,5x
EV / Sales 2023 20,1x
Nbr of Employees 824
Free-Float 99,0%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 18,06 €
Average target price 25,30 €
Spread / Average Target 40,1%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Igor Splawski Chief Scientific Officer
Malte Greune Chief Operating & Production Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-43.60%3 619
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478